Amgen Fails in Bid to Expand Use of Cancer Drug (AMGN)
A US drug advisory panel today denied by a 12-1 vote permission for Amgen Inc. (NASDAQ: AMGN) to market its Xgeva prostate cancer as a treatment for slowing the spread of tumors to bones in patients with advanced cases of…
A US drug advisory panel today denied by a 12-1 vote permission for Amgen Inc. (NASDAQ: AMGN) to market its Xgeva prostate cancer as a treatment for slowing the spread of tumors to bones in patients with advanced cases of prostate cancer. The FDA is expected to issue a final ruling on the drug in April.
If Amgen fails to gain approval for the drug, the company could lose about $1 billion in revenue in 2015, when the drug is forecast to generate $3-$4 billion in revenue for the company. Xgeva was approved in 2010 as a treatment to prevent bone pain and fractures caused by bone metastases and is also used to treat osteoporosis in menopausal women.
Amgen’s shares are down about -1.33% at $68.25 in a 52-week range of $47.66-$70.00.
Contact [email protected] for any questions or corrections.
Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.
He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.
